Benlysta Market Dynamics: A Comprehensive Forecast to 2030

ha aggiunto una foto Health

2025-01-11 12:20:40 -

Introduction to Benlysta (Belimumab) Benlysta (belimumab), developed by GlaxoSmithKline (GSK), is a monoclonal antibody designed to inhibit B-lymphocyte stimulator (BLyS), a key protein involved in B cell survival. Approved for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis, Benlysta represents a breakthrough in autoimmune disease management, reducing disease...

0 Commenti 0 condivisioni 38 Views 0 Anteprima